In-licensing Opportunity Assessment

Identify high-potential pipeline assets

Our in-licensing opportunity assessment framework enables pharmaceutical and healthcare companies to systematically identify, assess, and validate external assets—including drug candidates, technologies, and platforms—for potential integration into their portfolio through in-licensing agreements.

Our solution suite covers

Scientific & Technical Diligence Review of MoA, preclinical/clinical data.
Benchmarking against current standards of care and pipeline assets.
Identification of development or technical risks.
Commercial Due Diligence Market sizing and forecasting
Competitive landscape analysis (approved drugs, pipeline, emerging technologies).
Go-to-market strategy, pricing, and reimbursement landscape.
Differentiation and value proposition evaluation.
Regulatory and IP Review Regulatory pathway assessment (FDA, EMA, PMDA, etc.).
Assessment of prior interactions with regulatory agencies.
Financial Modeling & Valuation Risk-adjusted NPV (rNPV) models.
Milestone and royalty modeling.
Deal benchmarking based on industry comparables.
Sensitivity analysis to assess deal value under different scenarios.
Strategic Fit Analysis Fit with existing portfolio or pipeline.
Alignment with long-term corporate objectives.
Synergy potential with internal capabilities (e.g., R&D, sales force, manufacturing).

Market Potential

Approval / Development Status

Unmet Need

Competitive Intensity

Screening: Product Shortlisting Process​

Shortlisted Products​

Intense Product Prioritization Process​

Elaborate and Decisive

Product B (Preference 1)

Indication Potential – (Rare disease with >100,000 patients)

Competitive Intensity – (Poor pipeline and no approved drugs)

Unmet Needs/Pricing Ability – (Poor survival rates)

KOL Enthusiasm/SoC Possibility - (1st product to be approved)

Development & Regulatory – (Difficulty in patient recruitment and fixing endpoints in consultation with FDA)

Product D (Preference 2)

Indication Potential – (Epidemiology ~ 1,000,000 patients)

Competitive Intensity – (2 approved and 3 late-stage pipeline)

Unmet Needs/Pricing Ability – (5-year survival rate: 30%)

KOL Enthusiasm/SoC Possibility - (KOLs are looking for breakthrough therapies that improve survival)

Development & Regulatory – (The clinical trial design is well-defined with regulatory support for innovative products)

Data-intensive with weights and scores for each parameter, enabling flexibility for the client

Revenue Forecasting and Sensitivity Analysis

Estimate future revenue of drugs or portfolios

We specialize in data-driven revenue forecasting and precision sensitivity analysis designed to de-risk strategic decisions and elevate asset valuation across the drug lifecycle.

Whether you're assessing an in-licensing opportunity, planning a new launch, or evaluating the ROI of clinical investments, our modeling frameworks help you answer the questions that matter:

Target Population Estimated number of treatable patients based on epidemiological data (prevalence, incidence, mortality, morbidity)
Treatment Rate Expected adoption among eligible patients (new vs existing therapies), eligibility criteria, treatment rate, dosing regimen
Market Share % of patients likely to choose this product over competitors. Uptake curve, peak share, competition, access
Pricing Strategy List price, AWP (average wholesale price), WAC (wholesale acquisition cost), net price (discounts/rebates), price erosion
Reimbursement Landscape Coverage by payers, access hurdles, out-of-pocket costs
Launch Timing Impact of regulatory approval, sales ramp-up, and commercial readiness
Monte Carlo Simulations Run probabilistic scenarios to capture uncertainty
NPV & ROI Analysis Evaluate long-term financial return on development/commercialization
Sensitivity Analysis Variable testing (e.g. price, share, timing)

Baseline Patient Segment Epidemiology

Diagnosed and Treated Patient Pool

Impact of events

Estimating Patient Share of Product X (SDR / PMR)

By Price/Product Profile/Patient Segments/Any Other

Patient # on Product X

Dashboard

Epi. Assumptions

Diag. / Treatment Rate:

Patient Share Discounting:

Month-Year Of Launch:

Type Of Uptake Curve:

Compliance Rate:

Annual Price Change:

Also available as a module for an existing forecast model

Sensitivity Analysis​

Product X Units and Value

By Price/Product Profile/Patient Segments/Any Other

Click the Graph to Enlarge

Click the Graph to Enlarge

Sensitivity Analysis Module

Stress-test forecasts under various market scenarios

Our sensitivity analysis module evaluates how changes in key assumptions impact revenue projections — helping stakeholders understand risks, upside potential, and critical pressure points. we customize sensitivity analysis module evaluating how uncertainty in key inputs affects the outcomes of economic or valuation models — especially in licensing, pricing, and reimbursement decisions.

Key parameters, best practices and methodologies

Parameters Best Practices Methodologies
  • Clinical success probabilities (by phase)
  • Time to market and launch year
  • Peak sales, market share, and uptake curves
  • Pricing and reimbursement assumptions
  • Development and commercialization costs
  • Licensing terms (upfronts, milestones, royalties)
  • Use tornado charts to visualize impact of each variable
  • Present scenario comparisons (base, best, worst case)
  • Apply elasticity metrics to quantify sensitivity
  • Align ranges with empirical data or expert consensus
  • Univariate (One-way)
  • Multivariate (Two-way or more)
  • Threshold Analysis
  • Probabilistic (Monte Carlo)

The client must provide access to the existing forecast model, marking the base data for selected parameters.​

Selected parameters

For sensitivity analysis

Creation of Input Data Table

Change in the low and high case input values works through the forecast model flow and recalculates the values in Sensitivity Analysis.

Sensitivity Analysis Output​

Fast: 5-10 days for integration and output

Flexible: Ability to change the low and high case inputs

Longevity: Works as long as there is no change in the forecast flow (Assumptions can be changed)

Cost-effective: Automation made it possible

Sensitivity analysis to your completed forecast model at a cost that brings a ​

Problem-specific Consulting

Building the right story, and prioritizing the right asset

We offer targeted, expert-driven interventions that address specific challenges or decisions at different phases of a drug’s journey — from discovery to post-launch. Each phase has unique challenges, regulatory hurdles, and strategic decisions — and expert consulting can de-risk development, accelerate timelines, and maximize asset value

Our focus areas

Early-stage strategy Target product profiling, indication prioritization, competitive landscape mapping
Development optimization Value-based trial design, pricing-informed evidence generation, TPP refinement
Licensing & partnerships Asset valuation, deal structuring support, in-licensing feasibility, risk-adjusted forecasts
Commercialization readiness Access strategy, payer positioning, launch planning, value communication
Post-launch performance Market expansion, real-world value analysis, pricing renegotiations, portfolio rationalization

Reimbursement and funding of CAR-T therapies – Insights into pricing and reimbursement strategies

Problem Questions

Opportunities in developing companion diagnostics for solid tumors

Rationale of neuromodulation in migraine and depression understanding the regulatory and market aspects of such medical devices​

The benefits and gaps of POCT in infectious diseases – Findings and Recommendations ​​

Market potential and Recommendations on developing DTx for post-mastectomy breast cancer​

Problem Question​

Impact Factor Identification​

Facts and Key Information​

Interpretation and Assessment​

Insights and Recommendations​